BACKGROUND: Chronic myeloid leukemia (CML) can be treated effectively with tyrosine kinase inhibitor therapy directed at BCR-ABL, but access to care, medication cost, and adherence may be barriers to treatment. This study was designed to determine whether the insurance status at diagnosis influences CML patient outcomes. METHODS: The Surveillance, Epidemiology, and End Results database was used to identify 5784 patients, aged 15 years or older, who were diagnosed with CML between 2007 and 2012 and whose insurance status was documented at diagnosis. The primary outcome was 5-year overall survival (OS). Covariates of interest included the age at diagnosis, race, ethnicity, sex, county-level socioeconomic status, and marital status. OS was evaluated with a logrank test and Kaplan-Meier estimates. RESULTS: Among patients aged 15 to 64 years, insurance status was associated with OS (P <.001): being uninsured or having Medicaid was associated with worse 5-year OS in comparison with being insured (uninsured patients, 72.7%; Medicaid patients, 73.1%; insured patients, 86.6%). For patients who were 65 years old or older, insurance had less of an impact on OS (P 5.07), with similar 5-year OS rates for patients with Medicaid and those with other insurance (40.2% vs 43.4%). In a multivariate analysis of patients aged 15 to 64 years, both uninsured patients (hazard ratio [HR], 1.93; P <.001) and Medicaid patients (HR, 1.83; P <.001) had an increased hazard of death in comparison with insured patients; patients younger than 40 years, female patients, and married patients also had a lower hazard of death. CONCLUSION: These findings suggest that CML patients under the age of 65 years who are uninsured or have Medicaid have significantly worse survival than patients with other insurance coverage.
INTRODUCTION
The advent of tyrosine kinase inhibitors (TKIs) that target the aberrant BCR-ABL kinase in patients with chronic myeloid leukemia (CML) has ushered in a new era of targeted therapy in cancer care. CML was previously associated with a median survival of only 5 years, but more recently, clinical trials treating patients with frontline TKI therapy have reported longterm survival rates of approximately 90%, with the majority of patients achieving deep molecular remissions. 1, 2 Indeed, in some countries, the life expectancy of older patients receiving effective CML therapy may be nearing that of the general population. 3 There are a number of agents directed at BCR-ABL that are approved by the Food and Drug Administration for the treatment of CML; they include imatinib, dasatinib, and nilotinib in the upfront setting as well as bosutinib and ponatinib.
These significant advances are contingent upon access and adherence to effective and prolonged TKI therapy, taken once or twice daily, for an indefinite period of time. Indeed, nonadherence, even when as few as 10% of doses are missed, is associated with worse molecular response rates. [4] [5] [6] In the United States, a number of factors, including younger age, depression, and adverse effects from therapy 4, 6, 7 as well as insurance coverage and the amount of the copayment, 8 may be associated with nonadherence to oral chemotherapies. Each of the approved frontline TKIs costs approximately $100,000 per year, a price that may limit access to these highly effective therapies. 9 The amount that an individual pays depends largely on the extent to which individual insurance plans defray patient out-of-pocket costs as well as the availability of and eligibility for financial support programs. Insurance status affects the outcomes of a number of malignancies. For certain solid tumors, uninsured patients or those with Medicaid coverage have higher rates of cancer-specific death, present with later stage disease, and are less likely to receive cancer-directed surgery or radiation therapy. [10] [11] [12] The impact of insurance status on outcomes has not been as clear in hematologic malignancies such as acute leukemia. [13] [14] [15] Moreover, to date, no such studies have specifically investigated CML, a malignancy for which access to therapy has a potentially high impact on outcomes because of the availability of highly effective and tolerable oral agents.
For the current analysis, we used the Surveillance, Epidemiology, and End Results (SEER) database, an accepted standard for population cancer outcomes, to identify patients with CML who had insurance information documented at the time of their diagnosis. We hypothesized that a patient's insurance status at diagnosis would affect overall survival (OS) rates and other patient outcomes.
MATERIALS AND METHODS

Data Source and Study Population
We identified CML cases using the SEER 18 registries research database from the National Cancer Institute; released in April 2015 and based on the November 2014 submission. We included CML cases from SEER registries in Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles, San JoseMonterey, rural Georgia, greater California, Kentucky, Louisiana, New Jersey, and Georgia and for Alaska natives. SEER captures approximately 28% of the US population and is meant to be broadly representative of population demographics, income, and education. In accordance with the policy of our institution for SEER database research, institutional review board approval was not deemed necessary.
We included patients who were 15 years old or older at the time of their CML diagnosis. CML cases were identified according to International Classification of Diseases for Oncology (3rd edition) codes 9863 (CML) and 9875 (chronic myelogenous leukemia, BCR-ABL1-positive). We excluded patients with International Classification of Diseases for Oncology (3rd edition) code 9876 (atypical CML, BCR-ABL1-negative) because these patients are not routinely treated with TKI therapy. Patients diagnosed at autopsy or by death certificate only were excluded from this analysis. We also included only those patients with known follow-up. Because SEER first started reporting patient insurance information in 2007, we included only those whose initial diagnosis was between 2007 and 2012 and who had a documented insurance status in the database at the time of their diagnosis.
We classified the insurance status according to whether patients were uninsured at diagnosis, had Medicaid coverage at diagnosis, or had another form of insurance at the time of diagnosis; the last category could include Medicare, military coverage, or private payers such as health maintenance organizations, preferred provider organizations, and managed care (coded in SEER as insured or insured/no specifics). Patients with both Medicaid and Medicare are coded as Medicaid in SEER and were treated as such in this analysis. We excluded patients without a known insurance status from further analysis. Because patients who are 65 years old or older are eligible for Medicare, we excluded patients in this age group whose insurance status was reported as uninsured (n 5 16). The marital status was categorized as married (including domestic partnership and common-law marriage), single, or separated (including patients who were divorced or widowed).
Estimates of socioeconomic status were performed with county attributes from the US Census 2009-2013 American Community Survey 5-year data files, which were provided through the National Cancer Institute's SEER*Stat software. County-level estimates of the median household income, percentage with less than ninthgrade education, percentage with less than a high-school education, and percentage living below the poverty line were assigned to patients according to their state-county recode. We identified Medicaid copayments according to the state of residence with data from the Kaiser Family Foundation that were based on 2010 estimates. 16 
Analytical Approach
Patient characteristics were compared with the chi-square test and Fisher's exact test for categorical variables and with the Wilcoxon rank sum test for continuous variables. The median follow-up was calculated according to the method of Schemper and Smith. 17 OS was defined as the time from the CML diagnosis to death, with censoring at the time a patient was last known to be alive in SEER according to the vital status recode. OS was analyzed according to the insurance status with the Kaplan-Meier method and the log-rank test. Cox regression was performed separately within each age group to calculate predictors of OS, with variables of interest including insurance status, age, race, Hispanic ethnicity, sex, marital status, Medicaid copay, and county-level socioeconomic status. Patients without a recorded marital status (n 5 388) were censored in the multivariate analysis; however, when these patients were included within the separate category of unrecorded marital status, our findings did not significantly change. We dichotomized age for the multivariate analysis (<40 vs 40 years for patients under the age of 65 years and <75 vs 75 years for patients 65 years old or older). We dichotomized county-level variables at the median values for the entire cohort: household income ($56,460), poverty rates (13.9%), ninthgrade education rates (6.4%), high-school education rates (14.4%), and unemployment rates (9.9%). Forest plots were created with the %ForestMacro. Statistical analyses were performed with SAS software (SAS, Cary, NC). All P values were considered significant at the 2-sided .05 significance level.
RESULTS
We identified 5784 patients in the SEER database who were 15 years old or older, were diagnosed with CML between 2007 and 2012, and had their insurance status documented at the time of diagnosis. Among these patients, 337 were uninsured, 785 had Medicaid coverage, and 4662 had either private insurance or Medicare. The entire CML population was 57.4% male and 81% white, 12% black, and 7% other race. In the cohort, the marital status was reported as single for 1205 patients (22.3%), married for 3114 patients (57.7%), and separated, divorced, or widowed for 1077 patients (20.0%).
Non-Medicare Population (Age 15-64 Years)
We identified 3626 patients aged 15 to 64 years at the time of the CML diagnosis. In this group, 321 (8.9%) were uninsured, 595 (16.4%) had Medicaid coverage, and 2710 (74.7%) had insurance at the time of their diagnosis. In this age group, patients who were uninsured and patients who had Medicaid had median ages of 44 and 45 years, respectively, whereas those who were insured had a median age of 50 years (P < .001). The insurance status was associated with race (P < .001), Hispanic ethnicity (P < .001), and marital status (P < .001) in this cohort (Table 1 ). More patients in the uninsured or Medicaid group were nonwhite, Hispanic, or single. The insurance status varied according to the SEER registry of residence (P < .0001). For registries with at least 20 patients, the proportion of uninsured patients among younger patients ranged from 0% (Hawaii, 0 of 45 patients) to 18.73% (greater Georgia, 47 of 251 patients), and Medicaid rates (27) 175 (29) 369 (14) 39 (21) We identified 2142 patients who were 65 years old or older at the CML diagnosis; 190 (8.9%) had Medicaid coverage, and 1952 (91.1%) had other insurance, including Medicare. Within the older age group, Medicaid patients were more often female and nonwhite or Hispanic and were less often married ( Table 1 ). The insurance status varied according to the SEER registry of residence among those who were Medicare-eligible (P < .0001). Among registries with at least 20 patients, the proportion of Medicaid patients ranged from 0% (Utah, 0 of 31 patients) to 19.9% (Los Angeles, 33 of 166 patients; Supporting Table 2 [see online supporting information]).
Medicaid patients were significantly more likely to reside in counties with a larger population below the poverty line (16.1% vs 13.9%; P 5 .01) and without a highschool education (16.8% vs 13.8%; P < .001). There was no difference in county-level unemployment rates or median household income according to insurance status.
Patient Outcomes
The median follow-up for survivors was 32 months. Among patients aged 15 to 64 years, being uninsured or having Medicaid was associated with worse survival in comparison with being insured (P < .001). Five years after CML diagnosis, patients with insurance at the time of diagnosis had an 86.6% OS rate, whereas only 72.7% of uninsured patients and 73.1% of Medicaid patients were alive at 5 years (Fig. 1A) . For patients who were 65 years old or older, there was no statistically significant difference in OS between patients with Medicaid and those with other forms of insurance (40.2% vs 43.4%; Fig. 1B ). We performed Cox regression separately within each age group and adjusted it for the following: insurance status, age, race, ethnicity, sex, marital status, Medicaid copay, percentage living below the poverty line, percentage with less than a ninth-grade education, percentage with less than a high-school education, median household income, and unemployment rates. For patients aged 15 to 64 years, being uninsured or having Medicaid at the time of diagnosis was associated with an increased hazard for death, with insured patients serving as the comparator (uninsured hazard ratio [HR], 1.93 [P < .001]; Medicaid HR, 1.83 [P < .001]; Fig. 2 ). There was worse survival among patients who were 40 years old or older versus those younger than 40 years (HR, 2.44; P < .001) and among male patients versus female patients (HR, 1.31; P 5 .018). In addition, compared with married persons, single individuals had worse survival (HR, 1.65; P < .001). There was no association between outcomes and county-level socioeconomic metrics (Table 2) , and there was no significant association between SEER registry residence and survival after we adjusted for the insurance status, marital status, age, and patient sex.
For patients who were 65 years old or older at diagnosis, there was a trend toward worse survival in the Medicaid population that did not reach statistical significance (HR, 1.26; P 5 .073). Patients who were 75 years old or older had worse survival than those younger than 75 years (HR, 2.57; P < .001), and male patients had worse survival than females (HR, 1.17; P 5 .04). In the older patient population, compared with married patients, divorced/ widowed/separated patients had worse survival (HR, 1.35; P < .001), although single patients did not have worse outcomes (Table 2 ). Similarly to patients under the age of 65 years, after adjustments for the insurance status, marital status, age, and patient sex, there was no impact of SEER registry residence on survival.
DISCUSSION
Among newly diagnosed CML patients in the United
States, the insurance status at the time of diagnosis affected OS at the population level, specifically among patients under the age of 65 years. In this age group, patients who were uninsured or had Medicaid insurance had an approximately 2-fold hazard for death in comparison with patients with other insurance. In the Medicareeligible population (65 years old or older), insurance status did not have as large an impact on OS, although, similar to previous reports, [18] [19] [20] the overall outcomes of this group were generally poorer. Though not significant, the survival of Medicaid patients who were 65 years old or older was marginally lower than the survival of insured patients through the duration of the analysis (P 5 .07; Fig. 1B) . Interestingly, we found significant differences in survival according to whether patients were married or not at diagnosis, and male sex in both age groups was associated with worse survival. Together, our findings highlight the importance of considering payment structures when one is assessing broader population outcomes, including outcomes for highly treatable diseases such as CML. Figure 1 . Survival of (A) patients who were 15 to 64 years old and (B) patients who were 65 years old or older according to the insurance status at diagnosis. Among patients who were 15 to 64 years old, survival was worse among uninsured or Medicaid patients versus those who had insurance (P <.001). There was no significant difference in survival between patients with Medicaid and those with insurance for patients who were 65 years old or older at diagnosis (P 5.07).
Insurance programs in the United States vary widely and are the primary means of offsetting the cost of therapies for those with cancer. Younger patients commonly receive insurance through either employer-based or directpurchase plans, which provide coverage to approximately 67% of insured individuals. Government plans include Medicare, which is provided for patients 65 years old or older and for certain disease states, and Medicaid, which is offered to those at high risk because of various socioeconomic criteria. Approximately 10% of the population, until recently, remained without insurance. 21 Although such programs successfully extend access to care in the US population, it has been shown that even modest variations in plan characteristics, such as small differences in Medicaid copays, may reduce the use of prescription medications and increase emergency room visits. 22 In our study, the Medicaid population had outcomes rivaling those of the uninsured population; both were inferior in comparison with insured patients. Interestingly, in the Medicareeligible population of patients who were 65 years old or older, there was no significant difference in survival between Medicaid patients and other insured patients. One potential reason is that Medicare is reported along with other insurance carriers, whereas Medicaid is reported separately in SEER. We were, therefore, unable to determine whether there is any difference in outcomes between Medicare patients and patients with private insurance. If Medicare patients do more poorly, this would bias the study toward the null and could have affected our findings.
Because of the high cost of TKI therapy, patient assistance programs have been developed by manufacturers as well as organizations to help to defray this expense. However, these programs may have restrictions that exclude certain populations, including elderly patients on Medicare plans and undocumented immigrants. Indeed, previous research has identified cost sharing as a potential barrier to TKI initiation and adherence among CML patients on Medicare, 8, 23 and patients with higher copays are more likely to stop treatment within the first 6 months. 8 In 2007, it was estimated that approximately 20% of the US uninsured population were noncitizens; 24 undocumented immigrants constitute a disproportionate percentage of the uninsured and, with the Affordable Care Act, may represent up to 25% of the total uninsured population. 25, 26 In addition, because of the chronic nature of CML treatment, expenses associated with monitoring and follow-up can limit adherence. 23, 27 These Figure 2 . Forest plot of patient characteristics and the hazard of mortality among CML patients. Among younger patients (15-64 years old), having Medicaid, being uninsured, and being 40 years old or older, male, or single were associated with worse survival. Among those who were 65 years old or older, being 75 years old or older, male, or divorced/widowed was associated with worse survival. Because of limited patient numbers, American Indians (n 5 49) and patients of unknown race (n 5 81) were excluded from this analysis. CI indicates confidence interval; CML, chronic myeloid leukemia; HR, hazard ratio; LCL, lower confidence limit; UCL, upper confidence limit.
factors may have contributed to the poor outcomes seen among both nonelderly, uninsured patients and insured patients who were 65 years old or older in this analysis, many of whom would have had Medicare insurance. Several previous studies have explored the impact of insurance status on survival with other cancers. Particularly among younger adults with solid tumors, insurance status has been associated with later stages of disease at presentation, lower rates of surgical or radiation therapy, and higher rates of cancer-specific mortality. [10] [11] [12] [13] 15 The impact of insurance status on leukemia outcomes has been less clear, in part because there is less information about treatment and disease characteristics in many population-based data sets. In one study of younger patients with AML, being uninsured or having Medicaid was associated with worse survival. 13 However, in other studies of myelodysplastic syndromes, acute lymphoblastic leukemia, and acute myeloid leukemia, there was not a clear association between the insurance status and the outcomes. 14, 15 One challenge with assessing the impact of disparities on acute leukemias is the heterogeneity of these diseases, which has substantial influence on the treatment response and patient survival. Chronic-phase CML, in contrast, is a relatively uniform disease characterized and defined by the Philadelphia chromosome, and there are highly effective therapies available to those who can afford them either on their own or through insurance or assistance programs. Therefore, insurance coverage is an important consideration in their treatment, and variations in insurance plans or being uninsured may have a particularly high impact on patient outcomes because of the high cost of therapy. Indeed, there are concerns that the cost of TKI therapies for CML is unsustainable and may threaten access to effective treatment and the stability of our national health care systems in general. 9 A generic version of imatinib is now available in the United States, and this may provide an alternative agent with similar efficacy, 28, 29 although it is not yet known whether this will improve access to such agents.
It is also not clear whether insurance status itself influences patient outcomes directly (eg, by maintaining access to effective medications, physician visits, and general medical care and follow-up) or whether insurance status is a proxy for other variables that influence patient outcomes. In particular, patients with Medicaid may have other conditions that contribute to worse survival; however, some studies suggest that uninsured persons not enrolled in Medicaid may actually have fewer comorbidities. 30 We attempted to control for some aspect of the latter by including several county-level socioeconomic metrics in our analysis as well as state-level Medicaid copayment rates at the end of the study period. These variables did not appear to have a significant impact on patient outcomes in comparison with the insurance status itself. Insurance coverage varies between states, 31 but patient residence itself, as defined by the SEER registry, did not appear to significantly affect survival when we accounted for other variables, including the insurance status. Nonetheless, the county-and registry-level metrics in this analysis are indirect measurements; we did not have access to individual-level socioeconomic status factors, which could play a role in the findings that we report here.
The impact of marital status on patient outcomes has been noted in other cancers, 15, [32] [33] [34] [35] although this has not been well described in leukemias, including CML, to date. Our results also support the finding that being married at the time of a cancer diagnosis is associated with an improvement in survival. This was seen both among younger patients (married individuals had improved survival in comparison with those who were single) and among older patients (married individuals had improved survival in comparison with those who were divorced, widowed, or separated). The impact of marital status may be related to enhanced social support during and after cancer therapy 32, 36 and to treatment adherence 37, 38 and may also affect an individual's access to high-quality care and delays in presentation. 12, 39, 40 Our findings should also be interpreted within the context of the SEER registry, which, although robust and frequently used in population-based research, has some limitations. SEER is comprehensive within its regions and is representative of the US population, but insurance plans themselves may differ widely between states, and it is possible that our findings may not apply to other states with different insurance models. Moreover, this study population predates the Affordable Care Act, and it is not known whether changes in insurance access would alter our findings. [41] [42] [43] This will be an area of future investigation once more data are available because of data showing that out-of-pocket cancer treatment expenses have declined with the passage of the Affordable Care Act. 44 SEER is limited in that specific chemotherapy information, including information about oral chemotherapies, is not available. We also do not have specific data on adherence to any such treatment regimens. Lastly, SEER does not provide information on the phase of CML at presentation; although most patients with CML present with chronic-phase disease, it is possible that delays in or diminished access to care lead to more uninsured patients presenting with accelerated or blast-phase disease. However, this would not necessarily explain the similar results seen in the Medicaid population. In one analysis of 149 CML patients from an urban hospital with an underserved population, 96% of the patients nonetheless presented with chronic-phase disease. 45 The example of chronic-phase CML is the paragon for highly effective targeted cancer treatment, yet our findings suggest that such favorable outcomes may not be optimally realized in certain patient populations, in part because of their insurance coverage. This is particularly notable because it is younger patients for whom the impact appears to be greatest. Although CML affects relatively few patients each year, challenges in treating this patient cohort highlight barriers to providing effective care to the uninsured and underinsured that may be relevant across a broad spectrum of cancers. In particular, as more targeted, efficacious, and also more costly cancer therapies are developed for various malignancies, it will be increasingly important to ensure that all patients can access highly active therapies. Therefore, when we are treating patients with CML as well as other highly treatable cancers, resources may be needed to ensure access to treatment and to devise better strategies for suboptimal responses.
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